RU2011138951A - Пропротеины и способы их применения - Google Patents

Пропротеины и способы их применения Download PDF

Info

Publication number
RU2011138951A
RU2011138951A RU2011138951/10A RU2011138951A RU2011138951A RU 2011138951 A RU2011138951 A RU 2011138951A RU 2011138951/10 A RU2011138951/10 A RU 2011138951/10A RU 2011138951 A RU2011138951 A RU 2011138951A RU 2011138951 A RU2011138951 A RU 2011138951A
Authority
RU
Russia
Prior art keywords
functional protein
fragment
binding
protein
binding partner
Prior art date
Application number
RU2011138951/10A
Other languages
English (en)
Russian (ru)
Inventor
Нэнси Э. СТАГЛИАНО
Джеймс У. УЭСТ
Катрин КАМАТ
Пол Х. БЕССЕТТ
Джейсон СЭЙДЖЕРТ
Original Assignee
Сайтомкс Терапьютикс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Сайтомкс Терапьютикс, Инк. filed Critical Сайтомкс Терапьютикс, Инк.
Publication of RU2011138951A publication Critical patent/RU2011138951A/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/565—IFN-beta
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/57—IFN-gamma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6866—Interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/90—Fusion polypeptide containing a motif for post-translational modification

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
RU2011138951/10A 2009-02-23 2010-02-23 Пропротеины и способы их применения RU2011138951A (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15473009P 2009-02-23 2009-02-23
US61/154,730 2009-02-23
PCT/US2010/025121 WO2010096838A2 (en) 2009-02-23 2010-02-23 Proproteins and methods of use thereof

Publications (1)

Publication Number Publication Date
RU2011138951A true RU2011138951A (ru) 2013-03-27

Family

ID=42634501

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2011138951/10A RU2011138951A (ru) 2009-02-23 2010-02-23 Пропротеины и способы их применения

Country Status (9)

Country Link
US (7) US8399219B2 (cg-RX-API-DMAC7.html)
EP (1) EP2398494A4 (cg-RX-API-DMAC7.html)
JP (2) JP5861223B2 (cg-RX-API-DMAC7.html)
CN (1) CN102481341B (cg-RX-API-DMAC7.html)
AU (2) AU2010215761B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI1011384A2 (cg-RX-API-DMAC7.html)
CA (1) CA2753294A1 (cg-RX-API-DMAC7.html)
RU (1) RU2011138951A (cg-RX-API-DMAC7.html)
WO (1) WO2010096838A2 (cg-RX-API-DMAC7.html)

Families Citing this family (113)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009014726A1 (en) 2007-07-26 2009-01-29 The Regents Of The University Of California Methods for enhancing bacterial cell display of proteins and peptides
JP6035009B2 (ja) 2007-08-22 2016-11-30 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 活性化可能な結合ポリペプチドおよびその同定方法ならびに使用
WO2010004273A1 (en) 2008-07-07 2010-01-14 Oxford Nanopore Technologies Limited Base-detecting pore
US20110229877A1 (en) 2008-07-07 2011-09-22 Oxford Nanopore Technologies Limited Enzyme-pore constructs
GB0820927D0 (en) 2008-11-14 2008-12-24 Isis Innovation Method
CA2749339A1 (en) 2009-01-12 2010-07-15 Cytomx Therapeutics, Llc Modified antibody compositions, methods of making and using thereof
CN102482330A (zh) * 2009-01-30 2012-05-30 牛津纳米孔技术有限公司 酶突变体
KR101797773B1 (ko) 2009-01-30 2017-11-15 옥스포드 나노포어 테크놀로지즈 리미티드 막횡단 시퀀싱에서 핵산 구축물용 어댑터
CN102481341B (zh) 2009-02-23 2017-05-17 希托马克斯医疗有限公司 蛋白原及其使用方法
GB0905140D0 (en) 2009-03-25 2009-05-06 Isis Innovation Method
AU2012215135B9 (en) 2011-02-11 2017-03-09 Oxford Nanopore Technologies Limited Mutant pores
CA2843136C (en) 2011-07-25 2020-12-29 Oxford Nanopore Technologies Limited Hairpin loop method for double strand polynucleotide sequencing using transmembrane pores
EP2768977B1 (en) 2011-10-21 2015-09-23 Oxford Nanopore Technologies Limited Method of characterizing a target polynucleotide using a pore and a hel308 helicase
EP2798083B1 (en) 2011-12-29 2017-08-09 Oxford Nanopore Technologies Limited Method for characterising a polynucelotide by using a xpd helicase
WO2013098562A2 (en) 2011-12-29 2013-07-04 Oxford Nanopore Technologies Limited Enzyme method
KR102083695B1 (ko) 2012-04-10 2020-03-02 옥스포드 나노포어 테크놀로지즈 리미티드 돌연변이체 리세닌 기공
US11155860B2 (en) 2012-07-19 2021-10-26 Oxford Nanopore Technologies Ltd. SSB method
EP2875128B8 (en) 2012-07-19 2020-06-24 Oxford Nanopore Technologies Limited Modified helicases
JP6429773B2 (ja) 2012-07-19 2018-11-28 オックスフォード ナノポール テクノロジーズ リミテッド 酵素構築物
US9309510B2 (en) 2012-08-10 2016-04-12 Cytomx Therapeutics, Inc. Protease-resistant systems for polypeptide display and methods of making and using thereof
EP2895859B1 (en) 2012-09-12 2017-05-17 The University of Queensland Protease-based biosensor molecule
GB201314695D0 (en) 2013-08-16 2013-10-02 Oxford Nanopore Tech Ltd Method
SG11201507138RA (en) 2013-03-08 2015-10-29 Oxford Nanopore Tech Ltd Enzyme stalling method
GB201313477D0 (en) 2013-07-29 2013-09-11 Univ Leuven Kath Nanopore biosensors for detection of proteins and nucleic acids
KR102182485B1 (ko) * 2013-05-28 2020-11-25 카오슝 메디칼 유니버시티 단백질 약물의 불활성화를 위한 항체 로커
US20140364368A1 (en) * 2013-06-06 2014-12-11 Massachusetts Institute Of Technology Stimulus responsive nanocomplexes and methods of use thereof
EP3024851B1 (en) 2013-07-25 2018-05-09 CytomX Therapeutics, Inc. Multispecific antibodies, multispecific activatable antibodies and methods of using the same
AU2014321138A1 (en) 2013-09-12 2016-04-28 The University Of Queensland Bimolecular protease-based biosensor
KR20250051130A (ko) 2013-09-25 2025-04-16 싸이톰스 테라퓨틱스, 인크. 매트릭스 메탈로프로테이나제 기질 및 다른 절단성 모이어티 및 이의 사용 방법
GB201406151D0 (en) 2014-04-04 2014-05-21 Oxford Nanopore Tech Ltd Method
JP6677640B2 (ja) 2013-10-18 2020-04-08 オックスフォード ナノポール テクノロジーズ リミテッド 修飾酵素
JP6835586B2 (ja) 2014-01-31 2021-02-24 シトムクス セラピューティクス，インコーポレイティド マトリプターゼ及びｕ‐プラスミノーゲン活性化因子の基質及び他の切断可能部分、並びにその使用方法
GB201403096D0 (en) 2014-02-21 2014-04-09 Oxford Nanopore Tech Ltd Sample preparation method
US20170165334A1 (en) * 2015-12-11 2017-06-15 Tianxin Wang Methods to Treat Diseases with Protein, Peptide, Antigen Modification and Hemopurification
PL3536776T3 (pl) 2014-04-29 2024-03-25 Novartis Ag Nowe komórki kręgowców i sposoby ekspresji rekombinowanej polipeptydu będącego przedmiotem zainteresowania
GB201417712D0 (en) 2014-10-07 2014-11-19 Oxford Nanopore Tech Ltd Method
US10443097B2 (en) 2014-05-02 2019-10-15 Oxford Nanopore Technologies Ltd. Method of improving the movement of a target polynucleotide with respect to a transmembrane pore
CN106459960A (zh) 2014-05-13 2017-02-22 生物蛋白有限公司 条件活性生物蛋白
WO2016004383A1 (en) 2014-07-03 2016-01-07 City Of Hope Tumor-selective ctla-4 antagonists
US10669337B2 (en) 2014-07-25 2020-06-02 Cytomx Therapeutics, Inc. Bispecific anti-CD3 antibodies, bispecific activatable anti-CD3 antibodies, and methods of using the same
CN117164683A (zh) 2014-09-01 2023-12-05 弗拉芒区生物技术研究所 突变csgg孔
EP3204511B1 (en) 2014-10-07 2021-07-28 Oxford Nanopore Technologies Limited Mutant pores
GB201418159D0 (en) 2014-10-14 2014-11-26 Oxford Nanopore Tech Ltd Method
EP3244907B1 (en) 2015-01-13 2020-02-19 City of Hope Ctla4-binding protein peptide-linker masks
MA41374A (fr) 2015-01-20 2017-11-28 Cytomx Therapeutics Inc Substrats clivables par métalloprotéase matricielle et clivables par sérine protéase et procédés d'utilisation de ceux-ci
HK1252158A1 (zh) 2015-05-01 2019-05-17 Genentech, Inc. 掩蔽抗cd3抗体和使用方法
JP6857875B2 (ja) * 2015-05-19 2021-04-14 国立大学法人 熊本大学 新規な細胞膜透過性ペプチド
JP2018526972A (ja) 2015-06-16 2018-09-20 ジェネンテック， インコーポレイテッド 抗ｃｄ３抗体及び使用方法
BR102016018074A2 (pt) 2015-08-07 2021-11-16 ALX Oncology Inc. Construção variante de sirp-alfa, seu método de preparação e seus usos, molécula de ácido nucleico, vetor, célula hospedeira, e composição farmacêutica
RS62151B1 (sr) 2015-08-07 2021-08-31 Alx Oncology Inc Konstrukti koji sadrže sirp-alfa domen ili njegovu varijantu
US10758886B2 (en) * 2015-09-14 2020-09-01 Arizona Board Of Regents On Behalf Of Arizona State University Conditioned surfaces for in situ molecular array synthesis
BR112018008390A2 (pt) 2015-10-30 2018-11-27 Aleta Biotherapeutics Inc composições e métodos para transdução tumoral
MA43135A (fr) 2015-10-30 2018-09-05 Aleta Biotherapeutics Inc Compositions et méthodes pour le du traitement du cancer
US20210299265A1 (en) 2016-02-05 2021-09-30 Immunogen, Inc. Efficient process for preparing cell-binding agent-cytotoxic agent conjugates
ES2947230T3 (es) * 2016-03-22 2023-08-03 Hoffmann La Roche Moléculas biespecíficas para linfocitos T activadas por proteasa
GB201609220D0 (en) 2016-05-25 2016-07-06 Oxford Nanopore Tech Ltd Method
WO2017203268A1 (en) 2016-05-25 2017-11-30 Oxford Nanopore Technologies Limited Method
TW202515920A (zh) 2017-04-11 2025-04-16 美商因荷布瑞克斯生物科學公司 具有經受限cd3結合的多重特異性多肽構築體及使用其之方法
CA3067539A1 (en) * 2017-06-20 2018-12-27 The Board Of Regents Of The University Of Texas System Interferon prodrug for the treatment of cancer
CN111278461A (zh) 2017-08-16 2020-06-12 百时美施贵宝公司 可前药化抗体、其前药以及使用和制备方法
EP3694885A1 (en) 2017-10-14 2020-08-19 CytomX Therapeutics, Inc. Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereof
EP3769309A1 (en) 2018-03-20 2021-01-27 Cytomx Therapeutics Inc. Systems and methods for quantitative pharmacological modeling of activatable antibody species in mammalian subjects
TW202010757A (zh) 2018-04-11 2020-03-16 美商英伊布里克斯公司 具有經受限cd3結合的多重特異性多肽構築體以及相關方法及用途
CN113840832A (zh) 2018-05-14 2021-12-24 狼人治疗公司 可活化白介素-2多肽及其使用方法
WO2019222296A1 (en) * 2018-05-14 2019-11-21 Werewolf Therapeutics, Inc. Activatable interleukin 12 polypeptides and methods of use thereof
GB201807793D0 (en) 2018-05-14 2018-06-27 Oxford Nanopore Tech Ltd Method
KR20210038548A (ko) 2018-06-22 2021-04-07 큐진 인크. 사이토카인-기반 생체활성 약물 및 이의 사용 방법
WO2020023553A1 (en) 2018-07-24 2020-01-30 Inhibrx, Inc. Multispecific polypeptide constructs containing a constrained cd3 binding domain and a receptor binding region and methods of using the same
US12459980B2 (en) 2018-07-25 2025-11-04 AskGene Pharma, Inc. IL-21 prodrugs and methods of use thereof
KR20250154552A (ko) 2018-09-27 2025-10-28 실리오 디벨럽먼트, 인크. 마스킹된 사이토카인 폴리펩타이드
TW202028246A (zh) 2018-10-11 2020-08-01 美商英伊布里克斯公司 B7h3單域抗體及其治療性組合物
TW202028245A (zh) 2018-10-11 2020-08-01 美商英伊布里克斯公司 Dll3單域抗體及其治療性組合物
JP7453219B2 (ja) 2018-10-11 2024-03-19 インヒブリックス， インコーポレイテッド Ｐｄ－１単一ドメイン抗体およびその治療用組成物
TW202506736A (zh) 2018-10-11 2025-02-16 美商因荷布瑞克斯生物科學公司 5t4單域抗體及其治療性組合物
EP3890764A2 (en) 2018-12-06 2021-10-13 CytomX Therapeutics, Inc. Matrix metalloprotease-cleavable and serine or cysteine protease-cleavable substrates and methods of use thereof
AU2019395266A1 (en) * 2018-12-14 2021-06-17 Proviva Therapeutics (Hong Kong) Limited IL-15 compositions and methods of use thereof
US11136353B2 (en) * 2019-04-15 2021-10-05 Qwixel Therapeutics Llc Fusion protein composition(s) comprising masked type I interferons (IFNA and IFNB) for use in the treatment of cancer and methods thereof
CA3137512A1 (en) 2019-05-14 2020-11-19 Werewolf Therapeutics, Inc. Separation moieties and methods and use thereof
EP3976099A1 (en) 2019-05-31 2022-04-06 ALX Oncology Inc. Methods of treating cancer with sirp alpha fc fusion in combination with an immune checkpoint inhibitor
US20220251206A1 (en) 2019-06-11 2022-08-11 Bristol-Myers Squibb Company Anti-ctla4 antibody prodruggable (probody) at a cdr position
CN114341189A (zh) 2019-06-12 2022-04-12 奥美药业有限公司 全新il-15前药及其应用
WO2021055568A1 (en) * 2019-09-19 2021-03-25 Proviva Therapeutics (Hong Kong) Limited Il-2 compositions and methods of use thereof
MX2022004873A (es) 2019-10-23 2022-05-13 Cue Biopharma Inc Polipeptidos de tgf-?.
KR20220101147A (ko) 2019-11-14 2022-07-19 웨어울프 세라퓨틱스, 인크. 활성화가능한 사이토카인 폴리펩티드 및 이의 사용 방법
MX2022009306A (es) 2020-01-29 2022-09-26 Inhibrx Inc Loseta de nucleo de espuma densificada (dfc) con linea de anticuerpos de dominio individual de cd28 y constructos multivalentes y multiespecíficas de los mismos.
US20210252142A1 (en) * 2020-02-06 2021-08-19 Aetio Biotherapy, Inc. Compositions and methods for treating viral infections
MX2022011780A (es) 2020-04-09 2022-11-10 Cytomx Therapeutics Inc Composiciones que contienen anticuerpos activables.
CN115667523A (zh) 2020-04-10 2023-01-31 西托姆克斯治疗公司 可活化细胞因子构建体和相关组合物以及方法
JP2023550626A (ja) * 2020-11-23 2023-12-04 キュー バイオファーマ，インコーポレーテッド ＴＧＦ－βポリペプチド
KR20230113581A (ko) 2020-11-25 2023-07-31 실리오 디벨럽먼트, 인크. 종양 특이적 절단성 링커
AU2022237504A1 (en) * 2021-03-16 2023-10-05 Cytomx Therapeutics, Inc. Masked activatable cytokine constructs and related compositions and methods
IL308400A (en) 2021-05-13 2024-01-01 Alx Oncology Inc Combined therapies for cancer treatment
CA3221878A1 (en) * 2021-06-18 2022-12-22 David Stover Fusion protein composition(s) comprising masked type i interferons (ifna and ifnb) for use in the treatment of cancer and methods thereof
JP2024531338A (ja) * 2021-08-18 2024-08-29 ウェアウルフ セラピューティクス， インコーポレイテッド 活性化可能インターフェロンポリペプチド及びその使用方法
JP2024538706A (ja) 2021-10-08 2024-10-23 シートムエックス セラピューティクス，インコーポレイテッド 活性化可能サイトカイン構成体及び併用方法
IL311971A (en) 2021-10-08 2024-06-01 Cytomx Therapeutics Inc Activatable cytokine constructs and related compositions and methods
WO2023064791A1 (en) 2021-10-13 2023-04-20 Cytomx Therapeutics, Inc. Trimeric activatable cytokine constructs and related compositions and methods
EP4499685A1 (en) 2022-03-25 2025-02-05 CytomX Therapeutics, Inc. Activatable dual-anchored masked molecules and methods of use thereof
US20250215110A1 (en) 2022-04-01 2025-07-03 Cytomx Therapeutics, Inc. Activatable multispecific molecules and methods of use thereof
WO2023192606A2 (en) 2022-04-01 2023-10-05 Cytomx Therapeutics, Inc. Cd3-binding proteins and methods of use thereof
EP4565690A1 (en) 2022-08-01 2025-06-11 CytomX Therapeutics, Inc. Protease-cleavable moieties and methods of use thereof
TW202424183A (zh) 2022-08-01 2024-06-16 美商Ｃｙｔｏｍｘ生物製藥公司 蛋白酶可切割受質及其使用方法
TW202423953A (zh) 2022-08-01 2024-06-16 美商Ｃｙｔｏｍｘ生物製藥公司 蛋白酶可切割部分及其使用方法
AR130076A1 (es) 2022-08-01 2024-10-30 Cytomx Therapeutics Inc Restos escindibles por proteasas, y métodos de uso de los mismos
TW202426637A (zh) 2022-08-01 2024-07-01 美商Ｃｙｔｏｍｘ生物製藥公司 蛋白酶可切割受質及其使用方法
WO2024216170A2 (en) 2023-04-12 2024-10-17 Cytomx Therapeutics, Inc. Activatable cytokine constructs and related compositions and methods
CN120936384A (zh) 2023-04-12 2025-11-11 西托姆克斯治疗公司 掩蔽多肽、可活化细胞因子构建体以及相关组合物和方法
CN120958015A (zh) 2023-04-12 2025-11-14 西托姆克斯治疗公司 掩蔽多肽、可活化细胞因子构建体以及相关组合物和方法
WO2025007062A1 (en) * 2023-06-30 2025-01-02 The Regents Of The University Of California Pro-polypeptides and methods of using and designing the same
TW202517789A (zh) * 2023-07-04 2025-05-01 香港商禮邦醫藥（香港）有限公司 Ｋｌｋ１融合蛋白質的製備方法
WO2025038668A1 (en) 2023-08-14 2025-02-20 Voro Therapeutics, Inc. Therapeutic binding agents that conditionally promote myeloid cell activity against target cells and uses thereof
CN116930512B (zh) * 2023-09-19 2024-01-05 细胞生态海河实验室 一种用于脑卒中再发风险分析的生物标志物及其应用
WO2025240659A2 (en) 2024-05-14 2025-11-20 Cytomx Therapeutics, Inc. Activatable constructs, compositions and methods

Family Cites Families (141)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
JPS5686121A (en) 1979-12-14 1981-07-13 Teijin Ltd Antitumor proten complex and its preparation
US4867973A (en) 1984-08-31 1989-09-19 Cytogen Corporation Antibody-therapeutic agent conjugates
US4671958A (en) 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5306731A (en) 1985-06-14 1994-04-26 Massachusetts Eye And Ear Infirmary Method and products for treating the eye
US5849478A (en) 1986-08-14 1998-12-15 Cashman; Daniel P. Blocked-polymerase polynucleotide immunoassay method and kit
DE3853515T3 (de) 1987-05-21 2005-08-25 Micromet Ag Multifunktionelle proteine mit vorbestimmter zielsetzung.
US4975278A (en) 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
US4952394A (en) 1987-11-23 1990-08-28 Bristol-Myers Company Drug-monoclonal antibody conjugates
WO1989006692A1 (en) 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
US5720937A (en) 1988-01-12 1998-02-24 Genentech, Inc. In vivo tumor detection assay
US5322678A (en) 1988-02-17 1994-06-21 Neorx Corporation Alteration of pharmacokinetics of proteins by charge modification
US5144012A (en) 1988-08-08 1992-09-01 Eli Lilly And Company Cytotoxic drug conjugates
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
AU4128089A (en) 1988-09-15 1990-03-22 Rorer International (Overseas) Inc. Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same
US5010176A (en) 1988-11-10 1991-04-23 Eli Lilly And Company Antibody-drug conjugates
DE68925366T2 (de) 1988-11-18 1996-10-31 Univ California Konjugierte polypeptide und verfahren zur herstellung und verwendung
US5162218A (en) 1988-11-18 1992-11-10 The Regents Of The University Of California Conjugated polypeptides and methods for their preparation
KR0162259B1 (ko) 1989-12-05 1998-12-01 아미 펙터 감염성 병변 및 염증성 병변을 검출 및 치료하기 위한 키메라 항체
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
DK0590058T3 (da) 1991-06-14 2004-03-29 Genentech Inc Humaniseret heregulin-antistof
US5272253A (en) 1991-07-01 1993-12-21 Eli Lilly And Company Cluster conjugates of drugs with antibodies
US6107059A (en) 1992-04-29 2000-08-22 Affymax Technologies N.V. Peptide library and screening method
EP1550729B1 (en) 1992-09-25 2009-05-27 Avipep Pty Limited Target binding polypeptide comprising an IG-like VL domain linked to an IG-like VH domain
US5834247A (en) 1992-12-09 1998-11-10 New England Biolabs, Inc. Modified proteins comprising controllable intervening protein sequences or their elements methods of producing same and methods for purification of a target protein comprised by a modified protein
US5679548A (en) 1993-02-02 1997-10-21 The Scripps Research Institute Methods for producing polypeptide metal binding sites and compositions thereof
WO1994018221A1 (en) 1993-02-02 1994-08-18 The Scripps Research Institute Methods for producing polypeptide binding sites
US5556623A (en) 1993-03-30 1996-09-17 Eli Lilly And Company Antibody-drug conjugates
GB9322156D0 (en) 1993-10-27 1993-12-15 Univ Newcastel Upon Tyne Activation of molecules
US5733757A (en) 1995-12-15 1998-03-31 The Scripps Research Institute Aldolase catalytic antibody
US5468785A (en) 1994-04-15 1995-11-21 University Of Akron Cobaloxime photoinitiated free radical polymerizations
ES2297832T3 (es) 1994-08-19 2008-05-01 La Region Wallonne Conjugados que comprenden un agente antitumoral y su utilizacion.
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
JP4212111B2 (ja) 1995-05-03 2009-01-21 バイオエンハンスメンツ リミテッド 結合能力が光開裂性分子により可逆的に阻害される二重特異性抗体
US7060808B1 (en) 1995-06-07 2006-06-13 Imclone Systems Incorporated Humanized anti-EGF receptor monoclonal antibody
WO1997029131A1 (en) 1996-02-09 1997-08-14 Basf Aktiengesellschaft HUMAN ANTIBODIES THAT BIND HUMAN TNF$g(a)
GB9603507D0 (en) 1996-02-20 1996-04-17 Isis Innovation Antibody variants
US5866341A (en) 1996-04-03 1999-02-02 Chugai Pharmaceutical Co., Ltd. Compositions and methods for screening drug libraries
US5922845A (en) 1996-07-11 1999-07-13 Medarex, Inc. Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies
US5990286A (en) 1996-12-18 1999-11-23 Techniclone, Inc. Antibodies with reduced net positive charge
US20020032315A1 (en) 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
US6884879B1 (en) 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
ATE293640T1 (de) 1997-04-07 2005-05-15 Genentech Inc Anti-vegf antikörper
US7365166B2 (en) 1997-04-07 2008-04-29 Genentech, Inc. Anti-VEGF antibodies
US6323322B1 (en) 1997-04-30 2001-11-27 Enzon, Inc. Single-chain antigen-binding proteins capable of glycosylation, production and uses thereof
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
WO1998052966A1 (en) 1997-05-19 1998-11-26 The Johns Hopkins University School Of Medecine Tissue specific prodrug
US6326162B1 (en) 1997-07-25 2001-12-04 Bristol-Myers Squibb Pharma Company Assays and peptide substrate for determining aggrecan degrading metallo protease activity
US20030032103A1 (en) 1997-09-18 2003-02-13 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US6391311B1 (en) 1998-03-17 2002-05-21 Genentech, Inc. Polypeptides having homology to vascular endothelial cell growth factor and bone morphogenetic protein 1
AU760562B2 (en) 1997-12-05 2003-05-15 Scripps Research Institute, The Humanization of murine antibody
WO2000004192A1 (en) 1998-07-17 2000-01-27 Emory University Methods for detecting and mapping genes, mutations and variant polynucleotide sequences
US7157418B1 (en) 1998-07-22 2007-01-02 Osprey Pharmaceuticals, Ltd. Methods and compositions for treating secondary tissue damage and other inflammatory conditions and disorders
US6203989B1 (en) 1998-09-30 2001-03-20 Affymetrix, Inc. Methods and compositions for amplifying detectable signals in specific binding assays
US6180343B1 (en) 1998-10-08 2001-01-30 Rigel Pharmaceuticals, Inc. Green fluorescent protein fusions with random peptides
CZ300762B6 (cs) * 1998-10-16 2009-08-05 Biogen Idec Ma Inc. Fúzní proteiny interferonu-beta-1a a jejich použití
EE05627B1 (et) 1998-12-23 2013-02-15 Pfizer Inc. CTLA-4 vastased inimese monoklonaalsed antikehad
US6015557A (en) 1999-02-24 2000-01-18 Tobinick; Edward L. Tumor necrosis factor antagonists for the treatment of neurological disorders
US6534061B1 (en) 1999-04-12 2003-03-18 Genentech, Inc. Tumor necrosis factor receptor homologs and nucleic acids encoding the same
IL129427A0 (en) * 1999-04-13 2000-02-17 Yeda Res & Dev Preparation of biologically active molecules
CN1308347C (zh) * 1999-04-28 2007-04-04 德克萨斯大学董事会 用于通过选择性抑制vegf来治疗癌症的组合物和方法
US6268488B1 (en) 1999-05-25 2001-07-31 Barbas, Iii Carlos F. Prodrug activation using catalytic antibodies
US6903196B1 (en) 1999-06-17 2005-06-07 Utah Ventures Ii, L.P. Methods for identifying and isolating tissue-specific lumen-exposed molecules
US20040146516A1 (en) 1999-06-17 2004-07-29 Utah Ventures Ii L.P. Lumen-exposed molecules and methods for targeted delivery
EP1204682B1 (en) 1999-07-28 2010-11-17 Genentech, Inc. Compositions and methods for the treatment of tumors
ES2282133T3 (es) 1999-08-24 2007-10-16 Medarex, Inc. Anticuerpos frente a la ctla-4 humano y sus usos.
US20050208558A1 (en) 1999-10-19 2005-09-22 Applera Corporation Detection kits, such as nucleic acid arrays, for detecting the expression or 10,000 or more Drosophila genes and uses thereof
DE19952956A1 (de) 1999-11-03 2001-05-17 Acgt Progenomics Ag Verfahren zur Verbindung von molekularen Substanzen
US6548248B1 (en) * 1999-11-10 2003-04-15 Propper Manufacturing Co., Inc. DNA sterilization indicator
US6436703B1 (en) * 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
AU2001254857A1 (en) 2000-04-11 2001-10-23 Institut Pasteur Listeria monocytogenes genome, polypeptides and uses
US7514067B2 (en) 2000-04-25 2009-04-07 President And Fellows Of Harvard College Methods for tumor diagnosis and therapy
US20040181830A1 (en) * 2001-05-07 2004-09-16 Kovalic David K. Nucleic acid molecules and other molecules associated with plants and uses thereof for plant improvement
EP1286700A2 (en) * 2000-06-01 2003-03-05 Universite Catholique De Louvain Tumor activated prodrug compounds
JP2003534387A (ja) * 2000-06-01 2003-11-18 ユニべルシテ・カトリック・ドゥ・ルベン 腫瘍活性化プロドラッグ化合物、並びにこれらの製造方法及び使用方法
US20040014652A1 (en) 2000-06-01 2004-01-22 Andre Trouet Tumor activated prodrug compounds and methods of making and using the same
US6625945B2 (en) 2000-08-08 2003-09-30 Alfred D. Commins Balanced, multi-stud hold-down
DE10045592A1 (de) 2000-09-15 2002-03-28 Klaus Pfizenmaier Ein Antikörper-TNF-TNF Inhibitor Fusionsprotein (TNF-Selektokin) als zielspezifisches Prozytokin zur Tumortherapie
US7465790B2 (en) 2000-10-09 2008-12-16 Isis Innovation, Inc. Therapeutic antibodies
EP1324771B2 (en) 2000-10-09 2018-06-06 CytomX Therapeutics, Inc. Therapeutic and tolerance inducing antibodies
CA2432489A1 (en) 2001-01-04 2002-08-29 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Detection of protein conformation using a split ubiquitin reporter system
US7141392B2 (en) 2001-01-09 2006-11-28 Queen Mary And Westfield College Latent fusion protein
US7829084B2 (en) 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
EP1355675A1 (en) 2001-01-30 2003-10-29 Universite Catholique De Louvain Anti-tumor compounds
KR20030074839A (ko) 2001-02-19 2003-09-19 메르크 파텐트 게엠베하 감소된 면역원성을 갖는 개질 항-ｅｇｆｒ 항체
HUP0303171A2 (hu) 2001-02-19 2003-12-29 Merck Patent Gmbh Csökkentett immunogenitású mesterséges fehérjék
US6992174B2 (en) 2001-03-30 2006-01-31 Emd Lexigen Research Center Corp. Reducing the immunogenicity of fusion proteins
WO2003011317A1 (en) * 2001-07-25 2003-02-13 Lorantis Limited Modulators of notch signalling for use in immunotherapy
GB0118155D0 (en) 2001-07-25 2001-09-19 Lorantis Ltd Superantigen
DE60235761D1 (de) 2001-08-01 2010-05-06 Univ Bristol Clifton Isoform des vegfs
US20030082191A1 (en) 2001-08-29 2003-05-01 Poduslo Joseph F. Treatment for central nervous system disorders
US20040142325A1 (en) 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
US20030134824A1 (en) 2001-11-12 2003-07-17 Ronald Breslow Beta-cyclodextrin dimers and phthalocyanines and uses thereof
AU2002366303B2 (en) 2001-12-17 2007-09-20 University College Cardiff Consultants Limited Enzymatic cleavable reagents for specific delivery to disease sites
CA2475388A1 (en) 2002-02-14 2003-08-21 William J. Rutter Chimeric molecules for cleavage in a treated host
WO2003086459A1 (en) 2002-04-12 2003-10-23 Medarex, Inc. Methods of treatement using ctla-4 antibodies
US20040109855A1 (en) 2002-07-23 2004-06-10 Herman Waldmann Therapeutic antibodies with reduced side effect
WO2004021861A2 (en) 2002-09-03 2004-03-18 Vit Lauermann Targeted release
JP4351430B2 (ja) 2002-10-04 2009-10-28 財団法人癌研究会 ナノ黒鉛構造体に結合能を有するペプチド
AU2003288467A1 (en) 2002-12-13 2004-07-09 Immunomedics, Inc. Immunoconjugates with an intracellularly-cleavable linkage
CN1548537B (zh) 2002-12-27 2010-05-05 深圳市源兴生物医药科技有限公司 疫苗制备方法和抗肿瘤疫苗
CA2536357A1 (en) 2003-05-29 2004-12-23 The Scripps Research Institute Targeted delivery to legumain-expressing cells
US20050009110A1 (en) 2003-07-08 2005-01-13 Xiao-Jia Chang Methods of producing antibodies for diagnostics and therapeutics
CA2534055A1 (en) 2003-08-01 2005-02-10 Genentech, Inc. Antibody cdr polypeptide sequences with restricted diversity
DE602004023956D1 (de) 2003-08-18 2009-12-17 Univ California Polypeptid-display-bibliotheken und verfahren zur herstellung und verwendung davon
US20050106100A1 (en) 2003-09-03 2005-05-19 Harris Thomas D. Compounds containing matrix metalloproteinase substrates and methods of their use
US7431915B2 (en) 2003-10-31 2008-10-07 The Regents Of The University Of California Peptides whose uptake by cells is controllable
US7985401B2 (en) 2003-10-31 2011-07-26 The Regents Of The University Of California Peptides whose uptake by cells is controllable
WO2005051315A2 (en) 2003-11-24 2005-06-09 The Regents Of The University Of California On-demand cleavable linkers for radioconjugates for cancer imaging and therapy
WO2005067980A2 (en) 2004-01-12 2005-07-28 Pointilliste, Inc. Design of therapeutics and therapeutics
US7767792B2 (en) 2004-02-20 2010-08-03 Ludwig Institute For Cancer Research Ltd. Antibodies to EGF receptor epitope peptides
GB0404187D0 (en) 2004-02-25 2004-03-31 Biotransformations Ltd Binding agents
EP1579873A1 (en) 2004-03-23 2005-09-28 Complex Biosystems GmbH Polymeric prodrugs
US7541330B2 (en) 2004-06-15 2009-06-02 Kosan Biosciences Incorporated Conjugates with reduced adverse systemic effects
US20060234299A1 (en) 2004-11-16 2006-10-19 Avidia Research Institute Protein scaffolds and uses thereof
WO2006090813A1 (ja) 2005-02-25 2006-08-31 National University Corporation Hokkaido University 腫瘍組織で選択的に分解性を示す血中滞留性素子
WO2006108052A2 (en) 2005-04-06 2006-10-12 Genzyme Corporation Peg and polysialic lysosomal enzyme conjugates via acid labile linkers for therapeutic targeting
DE102005036542A1 (de) 2005-08-03 2007-02-08 Universität Stuttgart CTL-Prodrug
CA2620886C (en) 2005-08-31 2017-03-14 The Regents Of The University Of California Cellular libraries of peptide sequences (clips) and methods of using the same
US20090130776A1 (en) 2005-09-01 2009-05-21 Canon Kabushiki Kaisha Binding protein molecule
JP4567563B2 (ja) 2005-09-22 2010-10-20 富士通株式会社 携帯端末装置、ヒンジ装置、筒状部材及び光通信システム
EP1770099A1 (en) 2005-09-28 2007-04-04 University of Geneva Method of producing a modified (poly)peptide
EP1966242A1 (en) 2005-12-06 2008-09-10 Domantis Limited Ligands that have binding specificity for egfr and/or vegf and methods of use therefor
GB0604187D0 (en) 2006-03-02 2006-04-12 Fusion Antibodies Ltd Peptide and uses thereof
US20090246142A1 (en) 2006-03-10 2009-10-01 Massachusetts Institute Of Technology Triggered Self-Assembly of Nanoparticles In Vivo
JP2009529522A (ja) 2006-03-10 2009-08-20 ディアト 酵素で切断可能なリンカーを介して抗体に複合された抗癌剤
MX2008011874A (es) 2006-03-17 2009-01-07 Biogen Idec Inc Composiciones estabilizadas de polipeptidos.
JP4959226B2 (ja) * 2006-05-19 2012-06-20 独立行政法人産業技術総合研究所 スリーフィンガー様蛋白質ライブラリ
US8338482B2 (en) * 2006-07-20 2012-12-25 Wisconsin Alumni Research Foundation Modulating notch1 signaling pathway for treating neuroendocrine tumors
WO2008048680A2 (en) * 2006-10-19 2008-04-24 Maine Medical Center Research Institute Notch 2 signaling as a breast cancer suppressor pathway
ATE542830T1 (de) * 2006-12-04 2012-02-15 Pasteur Institut Als gerüst verwendeter ob-fold zur entwicklung neuer spezifischer bindemittel
WO2009018500A1 (en) 2007-07-31 2009-02-05 The Johns Hopkins University Polypeptide-nucleic acid conjugate for immunoprophylaxis or immunotherapy for neoplastic or infectious disorders
WO2009026274A1 (en) 2007-08-22 2009-02-26 Medarex, Inc. Site-specific attachment of drugs or other agents to engineered antibodies with c-terminal extensions
JP6035009B2 (ja) 2007-08-22 2016-11-30 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 活性化可能な結合ポリペプチドおよびその同定方法ならびに使用
MX2010003099A (es) 2007-09-21 2010-05-17 Univ California Interferon de objetivo demuestra actividades potentes apoptoticas y antitumorales.
EA201500156A3 (ru) 2008-01-03 2017-09-29 Дзе Скриппс Рисерч Инститьют Доставка антител посредством модульного домена распознавания
US20100189727A1 (en) 2008-12-08 2010-07-29 Tegopharm Corporation Masking Ligands For Reversible Inhibition Of Multivalent Compounds
CA2749339A1 (en) 2009-01-12 2010-07-15 Cytomx Therapeutics, Llc Modified antibody compositions, methods of making and using thereof
CN102481341B (zh) 2009-02-23 2017-05-17 希托马克斯医疗有限公司 蛋白原及其使用方法
US11136353B2 (en) * 2019-04-15 2021-10-05 Qwixel Therapeutics Llc Fusion protein composition(s) comprising masked type I interferons (IFNA and IFNB) for use in the treatment of cancer and methods thereof

Also Published As

Publication number Publication date
US8399219B2 (en) 2013-03-19
WO2010096838A2 (en) 2010-08-26
US20150203559A1 (en) 2015-07-23
JP5861223B2 (ja) 2016-02-16
AU2010215761B2 (en) 2017-04-06
JP2012520059A (ja) 2012-09-06
EP2398494A2 (en) 2011-12-28
US20100221212A1 (en) 2010-09-02
CN102481341A (zh) 2012-05-30
BRPI1011384A2 (pt) 2016-03-15
WO2010096838A3 (en) 2014-04-03
US8993266B2 (en) 2015-03-31
AU2010215761A1 (en) 2011-10-06
EP2398494A4 (en) 2015-10-28
AU2010215761A2 (en) 2012-04-05
CN102481341B (zh) 2017-05-17
US10513549B2 (en) 2019-12-24
US20170240608A1 (en) 2017-08-24
US20200308243A1 (en) 2020-10-01
US9644016B2 (en) 2017-05-09
US20230183308A1 (en) 2023-06-15
CA2753294A1 (en) 2010-08-26
JP2015193653A (ja) 2015-11-05
US20130101555A1 (en) 2013-04-25
AU2017201682A1 (en) 2017-03-30
US20230035290A1 (en) 2023-02-02

Similar Documents

Publication Publication Date Title
RU2011138951A (ru) Пропротеины и способы их применения
JP2012520059A5 (cg-RX-API-DMAC7.html)
JP7125453B2 (ja) 生物活性カーゴの経口送達のためのコリックス毒素由来融合分子
JP2022046569A5 (cg-RX-API-DMAC7.html)
JP6426103B2 (ja) ｃ−Ｍｅｔタンパク質アゴニスト
WO2020257412A1 (en) Combination therapy with cd13-targeted chimeric proteins or chimeric protein complexes
CN104995206A (zh) 新颖的胰岛素类似物及其用途
JP2017509594A5 (cg-RX-API-DMAC7.html)
CN1374969A (zh) Fap活化的抗肿瘤化合物
CN101255197A (zh) 血清白蛋白与白介素1受体拮抗剂的融合蛋白及应用
BG107613A (bg) Фузионен протеин от инхибитор на антитяло-цитокин-цитокин като продрога със специфична мишена
WO2014133327A1 (ko) 인슐린 위치 특이적 결합체
US20220226445A1 (en) Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo
CN1446261A (zh) 用于治疗癌症的修饰细胞因子
CA2657476C (en) Protein-binding methotrexate derivatives and medicaments containing the same
JPWO2019121906A5 (ja) Ｐｄ－ｌｉ抗原結合部位を有するｆｃ結合断片
JP2023538236A (ja) グルカゴン、ｇｌｐ－１及びｇｉｐ受容体の全てに対して活性を有する三重活性体を含む血圧降下用薬学組成物
JP2023518954A (ja) Ｎｇｒコンジュゲート及びその使用
JPWO2020123980A5 (cg-RX-API-DMAC7.html)
WO2008152508A2 (en) Cytokine conjugate
JP2022532445A (ja) 新規な中間体製造による持続型薬物結合体の製造方法
US5587457A (en) Neutrophil stimulating peptides
KR20220012227A (ko) Clec9a-기반 키메라 단백질 복합체
CN116284224B (zh) 一种结合Claudin 18.2的环肽及其应用
JP2004516240A (ja) 免疫応答のモジュレーションと、それに基づく方法

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20180109